CBLC and breast carcinoma: In this work, we identified mutations in E3 Cbl-c in a murine breast cancer and in human solid tumors that would inactivate the E3 activity of Cbl-c and in some cases, create dominant negative proteins that could interfere with the activity of endogenous wild type Cbl proteins.